CinRx partners with Graviton Bioscience to target ROCK2 in pulmonary arterial hypertension and other cardiovascular diseases
read at Endpoints ↗DealNeutral
CinRx announced a collaboration with Graviton Bioscience, led by Sam Waksal, to develop therapies that inhibit the ROCK2 enzyme.
The partnership will focus on pulmonary arterial hypertension (PAH) and other cardiovascular conditions, leveraging ROCK2's role in disease pathways.
Waksal previously pursued ROCK2 with Rezurock, a treatment for chronic graft-versus-host disease, and is now extending the target to cardio indications through this new alliance.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “CinRx teams with Sam Waksal's Graviton on ROCK2 for PAH, other cardio conditions”
read at Endpoints ↗95 words · retrieved 32m ago
comments(0)
5-min edit window · permanent after that